Video
Dr. Hafron explains the benefits of Jelmyto in UTUC since its approval
Author(s):
"We're seeing that it's beneficial to the patient—it’s easier, they don't require a general anesthetic, and we don't have to bring him to the hospital," says Dr. Hafron.
During the 2022 LUGPA Annual Meeting, Jason Hafron, MD, sat down with Urology Times® to discuss how his use of Jelmyto has evolved since the low-grade upper tract urothelial carcinoma treatment was approved in April 2020. Dr. Hafron is the Chief Medical Officer and Director of Clinical Research at the Michigan Institute of Urology and a professor of urology at Oakland University.
Related Videos
Related Content
